Gene therapy trials for sickle cell disease halted after two patients develop cancer
By Jocelyn Kaiser,
Science
| 02. 16. 2021
A company has stopped its clinical studies of a promising gene therapy for the blood disorder sickle cell disease after two people who participated developed leukemia-like cancer. Bluebird bio is now investigating whether a virus it uses to deliver a therapeutic gene caused the cancers, reviving old concerns about the risks of this approach.
It’s also possible the cancers stemmed from chemotherapy the patients received to prepare their bodies for the gene’s delivery. “This is really a sad development whatever the cause,” says Donald Kohn of the University of California, Los Angeles, who has led gene therapy trials for sickle cell and other diseases.
In the bluebird bio trials, scientists remove a patient’s blood stem cells and treat them in a dish with a modified virus related to HIV. It carries DNA encoding the oxygen-carrying protein hemoglobin and is intended to compensate for the patient’s defective gene for this molecule. After this step, called “ex vivo” because a patient’s cells are treated outside the body, doctors infuse the cells back into the person. Fourteen people who have received the latest...
Related Articles
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...
By Katherine Drabiak, Journal of Medical Ethics Forum | 08.07.2025
Adapted from Mitochondrial DNA at
National Human Genome Research Institute
Recently, media outlets around the world have been reporting on children born from pronuclear genome transfer (sometimes called “3-parent IVF,” “mitochondrial donation” or “mitochondrial replacement therapy”) at Newcastle Fertility Center...
By Nicky Hudson, The Conversation | 08.12.2025